Symbols / PRLD $3.43 +2.08%
PRLD Chart
About
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 215.63M |
| Enterprise Value | 197.67M | Income | -99.50M | Sales | 12.14M |
| Book/sh | 0.83 | Cash/sh | 1.25 | Dividend Yield | — |
| Payout | 0.00% | Employees | 79 | IPO | — |
| P/E | — | Forward P/E | -3.00 | PEG | — |
| P/S | 17.76 | P/B | 4.12 | P/C | — |
| EV/EBITDA | -1.95 | EV/Sales | 16.28 | Quick Ratio | 1.95 |
| Current Ratio | 1.99 | Debt/Eq | 25.92 | LT Debt/Eq | — |
| EPS (ttm) | -1.29 | EPS next Y | -1.15 | EPS Growth | — |
| Revenue Growth | 41.00% | Earnings | 2026-05-13 | ROA | -40.74% |
| ROE | -99.45% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -284.54% | Profit Margin | 0.00% | Shs Outstand | 43.77M |
| Shs Float | 14.66M | Short Float | 30.16% | Short Ratio | 6.50 |
| Short Interest | — | 52W High | 4.22 | 52W Low | 0.61 |
| Beta | 0.87 | Avg Volume | 405.99K | Volume | 135.63K |
| Target Price | $5.17 | Recom | Strong_buy | Prev Close | $3.36 |
| Price | $3.43 | Change | 2.08% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.17
Mean price target
2. Current target
$3.43
Latest analyst target
3. DCF / Fair value
$-9.82
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.43
Low
$4.50
High
$6.00
Mean
$5.17
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-11 | main | Citizens | Market Outperform → Market Outperform | $6 |
| 2025-09-23 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-08-18 | main | JMP Securities | Market Outperform → Market Outperform | $3 |
| 2025-05-05 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-04-29 | reit | JMP Securities | Market Outperform → Market Outperform | $4 |
| 2025-04-08 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-03-12 | reit | Citizens Capital Markets | Market Outperform → Market Outperform | $4 |
| 2024-12-11 | reit | JMP Securities | Market Outperform → Market Outperform | $4 |
| 2024-11-08 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-10-28 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-09-19 | up | HC Wainwright & Co. | Neutral → Buy | $5 |
| 2024-09-16 | reit | JMP Securities | Market Outperform → Market Outperform | $7 |
| 2024-09-16 | reit | HC Wainwright & Co. | Neutral → Neutral | $5 |
| 2024-09-10 | reit | HC Wainwright & Co. | Neutral → Neutral | $5 |
| 2024-08-15 | reit | HC Wainwright & Co. | Neutral → Neutral | $5 |
| 2024-03-13 | init | JMP Securities | — → Market Outperform | $7 |
| 2024-02-20 | down | HC Wainwright & Co. | Buy → Neutral | $5 |
| 2023-12-19 | down | Morgan Stanley | Equal-Weight → Underweight | $4 |
| 2023-11-07 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2023-10-19 | main | HC Wainwright & Co. | Buy → Buy | $6 |
- Why Did PRLD Stock Surge 13% Today? - Stocktwits ue, 03 Feb 2026 22
- PRLD - Prelude Therapeutics Inc Latest Stock News & Market Updates - Stock Titan Sun, 22 Feb 2026 13
- Prelude Therapeutics Incorporated's (NASDAQ:PRLD) Path To Profitability - Yahoo Finance Mon, 29 Dec 2025 08
- Prelude Therapeutics (PRLD) Price Target Increased by 23.81% to 4.42 - Nasdaq ue, 28 Oct 2025 07
- Prelude may sell up to $25M of common stock under existing ATM with Jefferies - TradingView hu, 12 Mar 2026 20
- Prelude Therapeutics files to offer up to $25 million in stock through Jefferies - Investing.com hu, 12 Mar 2026 21
- Prelude Therapeutics (PRLD) Q4 Loss Per Share Narrows Challenging Longstanding Bearish Narratives - simplywall.st ue, 10 Mar 2026 23
- Should I buy Prelude Therapeutics (PRLD) - Zacks Investment Research Mon, 24 Nov 2025 08
- Prelude Therapeutics (NASDAQ:PRLD) Posts Quarterly Earnings Results, Beats Estimates By $0.13 EPS - MarketBeat ue, 10 Mar 2026 12
- Prelude Therapeutics Establishes New ATM Equity Offering Facility - TipRanks hu, 12 Mar 2026 21
- Citizens Analyst Raises Price Target for Prelude Therapeutics (P - GuruFocus Wed, 11 Mar 2026 12
- Prelude (NASDAQ: PRLD) signs Incyte option for JAK2V617F; $60M and pipeline refocus - Stock Titan ue, 04 Nov 2025 08
- Prelude Therapeutics Incorporated's (NASDAQ:PRLD) 66% Share Price Plunge Could Signal Some Risk - simplywall.st Wed, 03 Dec 2025 08
- Prelude Therapeutics (NASDAQ:PRLD) Price Target Raised to $6.00 at Citizens Jmp - MarketBeat Wed, 11 Mar 2026 12
- Prelude Therapeutics (PRLD) Is Up 14.3% After Incyte Option Deal and Pipeline Shift Has the Bull Case Changed? - Yahoo Finance Wed, 05 Nov 2025 08
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 9375 | — | — | HUANG JANE | President | — | 2025-10-03 00:00:00 | D | nan |
| 1 | 9375 | — | — | HUANG JANE | President | — | 2025-07-03 00:00:00 | D | nan |
| 2 | 9375 | — | — | HUANG JANE | President | — | 2025-04-04 00:00:00 | D | nan |
| 3 | 675000 | — | Purchase at price 0.69 per share. | VADDI KRISHNA | Chief Executive Officer | — | 2025-03-25 00:00:00 | D | 467438.0 |
| 4 | 100000 | — | Purchase at price 0.69 per share. | COMBS ANDREW P | Officer | — | 2025-03-25 00:00:00 | D | 69250.0 |
| 5 | 20416 | — | Purchase at price 0.73 per share. | VADDI KRISHNA | Chief Executive Officer | — | 2025-03-21 00:00:00 | D | 14909.0 |
| 6 | 39105 | — | Purchase at price 0.75 per share. | VADDI KRISHNA | Chief Executive Officer | — | 2025-03-17 00:00:00 | D | 29460.0 |
| 7 | 97500 | — | Purchase at price 0.71 - 0.72 per share. | VADDI KRISHNA | Chief Executive Officer | — | 2025-03-13 00:00:00 | D | 69564.0 |
| 8 | 9375 | — | — | HUANG JANE | President | — | 2025-01-03 00:00:00 | D | nan |
| 9 | 5000 | — | Purchase at price 1.21 per share. | VADDI KRISHNA | Chief Executive Officer | — | 2024-12-31 00:00:00 | I | 6044.0 |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -102.86M | -137.94M | -131.11M | -122.22M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -99.50M | -127.17M | -121.83M | -115.44M |
| ReconciledDepreciation | 1.71M | 1.77M | 1.17M | 1.32M |
| EBITDA | -102.86M | -137.94M | -131.11M | -122.22M |
| EBIT | -104.57M | -139.71M | -132.28M | -123.54M |
| NormalizedIncome | -99.50M | -127.17M | -121.83M | -115.44M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -99.50M | -127.17M | -121.83M | -115.44M |
| TotalExpenses | 116.71M | 146.71M | 132.28M | 123.54M |
| TotalOperatingIncomeAsReported | -104.57M | -139.71M | -132.28M | -123.54M |
| DilutedAverageShares | 75.81M | 60.36M | 47.37M | 46.05M |
| BasicAverageShares | 75.81M | 60.36M | 47.37M | 46.05M |
| DilutedEPS | -1.68 | -2.02 | -2.44 | -2.43 |
| BasicEPS | -1.68 | -2.02 | -2.44 | -2.43 |
| DilutedNIAvailtoComStockholders | -99.50M | -127.17M | -121.83M | -115.44M |
| NetIncomeCommonStockholders | -99.50M | -127.17M | -121.83M | -115.44M |
| NetIncome | -99.50M | -127.17M | -121.83M | -115.44M |
| NetIncomeIncludingNoncontrollingInterests | -99.50M | -127.17M | -121.83M | -115.44M |
| NetIncomeContinuousOperations | -99.50M | -127.17M | -121.83M | -115.44M |
| PretaxIncome | -99.50M | -127.17M | -121.83M | -115.44M |
| OtherIncomeExpense | 5.07M | 12.54M | 10.45M | 8.10M |
| OtherNonOperatingIncomeExpenses | 5.07M | 12.54M | 10.45M | 8.10M |
| OperatingIncome | -104.57M | -139.71M | -132.28M | -123.54M |
| OperatingExpense | 116.71M | 146.71M | 132.28M | 123.54M |
| ResearchAndDevelopment | 94.30M | 118.00M | 103.39M | 92.89M |
| SellingGeneralAndAdministration | 22.41M | 28.72M | 28.88M | 30.65M |
| GeneralAndAdministrativeExpense | 22.41M | 28.72M | 28.88M | 30.65M |
| OtherGandA | 22.41M | 28.72M | 28.88M | 30.65M |
| TotalRevenue | 12.14M | 7.00M | 0.00 | 0.00 |
| OperatingRevenue | 12.14M | 7.00M | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 62.95M | 55.15M | 54.91M | 47.90M |
| ShareIssued | 62.95M | 55.15M | 54.91M | 47.90M |
| TotalDebt | 17.79M | 18.02M | 16.89M | 1.83M |
| TangibleBookValue | 68.64M | 131.46M | 237.09M | 195.44M |
| InvestedCapital | 68.64M | 131.46M | 237.09M | 195.44M |
| WorkingCapital | 52.70M | 110.25M | 213.76M | 182.68M |
| NetTangibleAssets | 68.64M | 131.46M | 237.09M | 195.44M |
| CapitalLeaseObligations | 17.79M | 18.02M | 16.89M | 1.83M |
| CommonStockEquity | 68.64M | 131.46M | 237.09M | 195.44M |
| TotalCapitalization | 68.64M | 131.46M | 237.09M | 195.44M |
| TotalEquityGrossMinorityInterest | 68.64M | 131.46M | 237.09M | 195.44M |
| StockholdersEquity | 68.64M | 131.46M | 237.09M | 195.44M |
| GainsLossesNotAffectingRetainedEarnings | 8.00K | 35.00K | 223.00K | -1.69M |
| OtherEquityAdjustments | 8.00K | 35.00K | 223.00K | -1.69M |
| RetainedEarnings | -683.06M | -583.56M | -456.39M | -334.56M |
| AdditionalPaidInCapital | 751.68M | 714.98M | 693.25M | 531.68M |
| CapitalStock | 6.00K | 5.00K | 5.00K | 5.00K |
| CommonStock | 6.00K | 5.00K | 5.00K | 5.00K |
| TotalLiabilitiesNetMinorityInterest | 72.68M | 44.06M | 40.58M | 25.06M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 19.68M | 18.41M | 18.75M | 3.36M |
| OtherNonCurrentLiabilities | 2.84M | 3.09M | 3.34M | 3.36M |
| NonCurrentDeferredLiabilities | 1.80M | 0.00 | ||
| NonCurrentDeferredRevenue | 1.80M | 0.00 | ||
| LongTermDebtAndCapitalLeaseObligation | 15.04M | 15.32M | 15.41M | 0.00 |
| LongTermCapitalLeaseObligation | 15.04M | 15.32M | 15.41M | 0.00 |
| CurrentLiabilities | 52.99M | 25.64M | 21.83M | 21.70M |
| OtherCurrentLiabilities | 965.00K | 771.00K | 945.00K | 524.00K |
| CurrentDeferredLiabilities | 33.73M | 0.00 | ||
| CurrentDeferredRevenue | 33.73M | 0.00 | ||
| CurrentDebtAndCapitalLeaseObligation | 2.74M | 2.70M | 1.48M | 1.83M |
| CurrentCapitalLeaseObligation | 2.74M | 2.70M | 1.48M | 1.83M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 7.14M | 9.02M | 9.16M | 5.68M |
| PayablesAndAccruedExpenses | 8.41M | 13.15M | 10.25M | 13.66M |
| CurrentAccruedExpenses | 4.43M | 5.42M | 5.67M | 6.89M |
| Payables | 3.98M | 7.73M | 4.58M | 6.78M |
| AccountsPayable | 3.98M | 7.73M | 4.58M | 6.78M |
| TotalAssets | 141.31M | 175.51M | 277.67M | 220.50M |
| TotalNonCurrentAssets | 35.62M | 39.62M | 42.08M | 16.12M |
| OtherNonCurrentAssets | 3.35M | 4.15M | 4.34M | 9.42M |
| NetPPE | 32.28M | 35.47M | 37.74M | 6.70M |
| AccumulatedDepreciation | -6.93M | -5.26M | -3.57M | -3.32M |
| GrossPPE | 39.21M | 40.72M | 41.30M | 10.02M |
| Leases | 1.71M | 1.70M | 1.58M | 875.00K |
| ConstructionInProgress | 0.00 | 338.00K | 1.64M | 668.00K |
| OtherProperties | 35.10M | 36.62M | 37.05M | 7.42M |
| MachineryFurnitureEquipment | 2.40M | 2.40M | 2.33M | 87.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 105.69M | 135.90M | 235.59M | 204.38M |
| OtherCurrentAssets | 2.48M | 2.28M | 2.65M | 2.65M |
| PrepaidAssets | 3.88M | |||
| CashCashEquivalentsAndShortTermInvestments | 103.21M | 133.61M | 232.94M | 201.73M |
| OtherShortTermInvestments | 67.96M | 121.14M | 207.64M | 171.12M |
| CashAndCashEquivalents | 35.26M | 12.47M | 25.29M | 30.61M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -56.37M | -103.65M | -110.58M | -86.75M |
| RepaymentOfDebt | -208.00K | -395.00K | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 24.88M | 0.00 | 135.73M | 0.00 |
| CapitalExpenditure | -67.00K | -764.00K | -3.51M | -3.02M |
| EndCashPosition | 38.49M | 16.52M | 29.34M | 34.65M |
| BeginningCashPosition | 16.52M | 29.34M | 34.65M | 35.87M |
| ChangesInCash | 21.97M | -12.82M | -5.31M | -1.22M |
| FinancingCashFlow | 24.82M | -120.00K | 136.40M | 815.00K |
| CashFlowFromContinuingFinancingActivities | 24.82M | -120.00K | 136.40M | 815.00K |
| NetOtherFinancingCharges | -17.00K | -164.00K | -17.00K | -303.00K |
| ProceedsFromStockOptionExercised | 166.00K | 439.00K | 681.00K | 815.00K |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 24.88M | 0.00 | 135.73M | 0.00 |
| CommonStockIssuance | 24.88M | 0.00 | 135.73M | 0.00 |
| NetIssuancePaymentsOfDebt | -208.00K | -395.00K | 0.00 | 0.00 |
| NetLongTermDebtIssuance | -208.00K | -395.00K | 0.00 | 0.00 |
| LongTermDebtPayments | -208.00K | -395.00K | 0.00 | 0.00 |
| InvestingCashFlow | 53.46M | 90.19M | -34.65M | 81.69M |
| CashFlowFromContinuingInvestingActivities | 53.46M | 90.19M | -34.65M | 81.69M |
| NetInvestmentPurchaseAndSale | 53.53M | 90.95M | -31.13M | 84.71M |
| SaleOfInvestment | 154.39M | 143.65M | 190.50M | 203.93M |
| PurchaseOfInvestment | -100.87M | -52.69M | -221.63M | -119.22M |
| NetPPEPurchaseAndSale | -67.00K | -764.00K | -3.51M | -3.02M |
| PurchaseOfPPE | -67.00K | -764.00K | -3.51M | -3.02M |
| OperatingCashFlow | -56.30M | -102.89M | -107.06M | -83.73M |
| CashFlowFromContinuingOperatingActivities | -56.30M | -102.89M | -107.06M | -83.73M |
| ChangeInWorkingCapital | 28.41M | 4.22M | -10.48M | 932.00K |
| ChangeInOtherWorkingCapital | 35.53M | |||
| ChangeInOtherCurrentLiabilities | -28.00K | 1.05M | -1.62M | -1.71M |
| ChangeInPayablesAndAccruedExpense | -6.90M | 2.50M | 252.00K | 6.49M |
| ChangeInAccruedExpense | -2.98M | -808.00K | 2.52M | 6.83M |
| ChangeInPayable | -3.92M | 3.31M | -2.27M | -347.00K |
| ChangeInAccountPayable | -3.92M | 3.31M | -2.27M | -347.00K |
| ChangeInPrepaidAssets | -197.00K | 668.00K | -9.11M | -3.84M |
| OtherNonCashItems | 1.53M | 1.59M | 1.94M | 1.72M |
| StockBasedCompensation | 11.91M | 21.34M | 25.62M | 25.14M |
| AmortizationOfSecurities | -371.00K | -4.64M | -3.47M | 2.59M |
| DepreciationAmortizationDepletion | 1.71M | 1.77M | 1.17M | 1.32M |
| DepreciationAndAmortization | 1.71M | 1.77M | 1.17M | 1.32M |
| GainLossOnSaleOfPPE | 0.00 | |||
| NetIncomeFromContinuingOperations | -99.50M | -127.17M | -121.83M | -115.44M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PRLD
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|